Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 17, 2016 - Issue 2
Submit an article Journal homepage
921
Views
22
CrossRef citations to date
0
Altmetric
Reviews

New hepatitis C therapies for special patient populations

Vincent SorianoInfectious Diseases Unit, La Paz University Hospital, Madrid28046, SpainCorrespondence[email protected]
,
Pablo LabargaDepartment of Internal Medicine, La Luz Clinic, Madrid 28035, Spain
,
Carmen de MendozaDepartment of Internal Medicine, Puerta de Hierro Research Institute & University Hospital, Majadahonda 28035, Spain
,
José V Fernández-MonteroDepartment of Infectious Diseases, University Hospital Crosshouse, Kilmarnock, UK
,
Isabella EspositoInfectious Diseases Unit, La Paz University Hospital, Madrid28046, Spain
,
Laura Benítez-GutiérrezDepartment of Internal Medicine, Puerta de Hierro Research Institute & University Hospital, Majadahonda 28035, Spain
,
José M PeñaInfectious Diseases Unit, La Paz University Hospital, Madrid28046, Spain
&
Pablo BarreiroInfectious Diseases Unit, La Paz University Hospital, Madrid28046, Spain
 show all
Pages 217-229 | Received 01 Jul 2015, Accepted 22 Oct 2015, Published online: 23 Nov 2015

Bibliography

This manuscript is a brief summary of major drug interactions of new oral hepatitis C drugs. It includes very helpful tables.

  • Soriano V, Labarga P, Barreiro P, et al. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol. 2015;11:333–341.
  • Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013;58:792–800.

This is a pivotal review on major drug-drug interactions of new oral HCV drugs, written by pharmacologists with large expertise in antivirals and robust clinical knowledge.

  • Kiser J, Burton J, Everson G. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596–606.

This review summarizes the most relevant information on mechanisms of drug interactions expected and/or clinically observed using new oral hepatitis C drugs.

  • Ahmad T, Yin P, Saffitz J, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology. 2015;62:409–416.
  • Soriano V, Esposito I. Caution with new oral hepatitis C drugs. AIDS Rev. 2015;17:121–122.
  • Karageorgopoulos D, El-Sherif O, Bhagani S, et al. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/HCV coinfection. Curr Opin Infect Dis. 2014;27:36–45.

This is a comprehensive and updated review on the major drug–drug interactions between antivirals in HIV-HCV coinfected patients.

  • Esposito I, Labarga P, Barreiro P, et al. Dual antiviral therapy for HIV and HCV – drug interactions and side effects. Expert Opin Drug Saf. 2015;14:1421–1434.
  • Tischer S, Fontana R. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol. 2014;60:872–884.
  • Toussaint-Miller K, Andres J. Treatment considerations for unique patients populations with HCV genotype 1 infection. Ann Pharmacother. 2015;49:1015–1030.
  • Gane E, Roberts S, Stedman C, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376:1467–1475.
  • Wiktor S. Deciding who should be treated for hepatitis C infection in a rapidly changing therapeutic landscape. Hepatology. 2015;62:13–15.
  • Jensen D, O’Leary J, Pockros P, et al. Safety and efficacy of sofosbuvir-containing regimens for hepatitis C: real-world experience in a diverse, longitudinal observational cohort. AASLD 2014, Boston, MA. November 7-11 2014 [abstract 45]. Hepatology. 2014;60(suppl):219A.
  • Dieterich D, Bacon B, Flamm S, et al. Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real world, heterogeneous population. AASLD 2014, Boston, MA. November 7-11 2014 [abstract 46]. Hepatology. 2014;60(suppl):220A.
  • Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–1992.
  • Bourliere M, Sulkowski M, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. AASLD 2014, Boston, MA [abstract 82]. Hepatology. 2014;60(suppl):239A.
  • Hézode C, Asselah T, Reddy K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502–2509.
  • Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1075–1086.
  • Poordad F, Sievert W, Mollison L, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir and beclabuvir for non-cirrhotic patients with HCV genotype 1 infection. JAMA. 2015;313:1728–1735.
  • Muir A, Poordad F, Lalezari J, et al. Daclatasvir in combination with asunaprevir and beclabusvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015;313:1736–1744.
  • Hassanein T, Sims K, Bennett M, et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabusvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol. 2015;62:1204–1206.
  • Treviño A, De Mendoza C, Parra P, et al. Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. Antivir Ther. 2011;16:413–416.
  • Poveda E, Wyles D, Mena A, et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014;108:181–191.
  • Nguyen L, Gray E, Dean J, et al Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype 1-infected individuals. Antivir Ther. 2015 Apr 29. DOI:10.3851/IMP2964. [Epub ahead of print].
  • Barreiro P, Fernandez-Montero JV, De Mendoza C, et al. Towards hepatitis C eradication from the HIV-infected population. Antiviral Res. 2014;105:1–7.
  • Jiménez-Nácher I, Alvarez E, Morello J, et al. Approaches for understanding and predicting drug interactions in HIV-infected patients. Expert Opin Drug Metab Toxicol. 2011;7:457–477.
  • You D, Pockros P. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother. 2013;14:2581–2589.
  • Gentile I, Borgia F, Buonomo A, et al. ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem. 2014;21:3261–3270.
  • Sofia M. Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C? Antivir Res. 2014;107:119–124.
  • Soriano V, Vispo E, De Mendoza C, et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother. 2013;14:1161–1170.
  • Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Aids. 2009;23:689–696.

This is a pivotal study that establishes the rate, timing and tubular nature of renal damage in patients exposed to tenofovir.

  • Rockstroh J, Puoti M, Rodriguez-Torres M, et al. Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV coinfected patients with HCV GT1-4 infection: the PHOTON-1 and −2 trials. AASLD 2014, Boston, MA [abstract 195]. Hepatology. 2014;60(suppl):295A.
  • Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV coinfection. JAMA. 2015;313:1232–1239.
  • Gentile I, Buonomo A, Borgia F, et al. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs. 2014;23:561–571.
  • Aghemo A, De Francesco R. Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. Gut. 2015;64:860–862.
  • Wyles D, Ruane P, Sulkowski M, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714–725.
  • Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705–713.
  • Sulkowski M, Eron J, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223–1231.
  • Piroth L, Paniez H, Taburet A, et al. High cure rate with 24 weeks of daclatasvir-based quadruple therapy in treatment-experienced, null-responder patients with HIV/HCV genotypes 1-4 coinfection: the ANRS HC30 QUADRIH study. Clin Infect Dis. 2015;61:817–825.
  • Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1087–1097.
  • Stock P, Terrault N. HIV and liver transplantation: Hepatitis C is the last hurdle. Hepatology. 2015;61:1747–1754.
  • Kwo P, Badshah M. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage liver disease. Curr Opin Organ Transplant. 2015;20:235–241.
  • Pellicelli A, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014;46:923–927.
  • Kwo P, Mantry P, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375–2382.
  • Menon R, Badri P, Wang T, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015;63:20–29.
  • Stine J, Intagliata N, Shah N, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci. 2015;60:1031–1035.
  • Soriano V, Barreiro P, De Mendoza C, et al. Hepatic decompensation with sofosbuvir plus simeprevir in a patient with Child-Pugh B compensated cirrhosis. Antivir Ther. 2015 Jun 4. DOI:10.3851/IMP2969. [Epub ahead of print].
  • Charlton M, Everson G, Flamm S, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–659.
  • Poole R. Daclatasvir + Asunaprevir: first global approval. Drugs. 2014;74:1559–1571.
  • Dyson J, Hutchinson J, Harrison L, et al Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2015 Aug 29. pii: S0168-8278(15)00589-9. DOI:10.1016/j.jhep.2015.07.041. [Epub ahead of print].
  • Asselah T, Bruno S, Craxi A. HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir and ribavirin solve the need for treatment? J Hepatol. 2014;61:1430–1433.
  • Ferenci P, Kozbial K, Mandorfer M, et al. HCV targeting of patients with cirrhosis. J Hepatol. 2015;63:1015–1022.
  • Saxena V, Nyberg L, Pauly M, et al. Safety and Efficacy of simeprevir/sofosbuvir in hepatitis C infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62:715–725.
  • Jacobson I, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh B cirrhosis (C-SALT part A). EASL, Vienna, Austria [abstract O008]. J Hepatol. 2015;62(suppl):193–194.
  • Poordad F, Schiff E, Vierling J, et al. Daclatasvir, sofosbuvir and ribavirin combination for HCV patients with advanced cirrhosis or postransplant recurrence: phase 3 ALLY-1 study. EASL, Vienna, Austria [abstract L08]. J Hepatol. 2015;62(suppl):261.
  • Gentile I, Buonomo A, Borgia G. Dasabuvir: A non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection. Rev Recent Clin Trials. 2014;9:115–123.
  • Khatri A, Dutta S, Marbury T, et al. The pharmacokinetics and safety of the DAA ABT-450/r, ombitasvir with/without dasabuvir in subjects with mild, moderate and severe renal impairment compared to subjects with normal renal function. AASLD 2014, Boston, MA [abstract 238]. Hepatology. 2014;60(suppl):320A.
  • Stirnimann G. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother. 2014;15:2609–2622.
  • Gentile I, Buonomo A, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther. 2014;12:1033–1043.
  • Roth D, Nelson D, Bruchfeld A, et al. C-SURFER: Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patient with HCV genotype 1 infection and chronic kidney disease. EASL, Vienna, Austria [abstract LP02]. J Hepatol. 2015;62(suppl):263–264.
  • Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol. 2014;20:14559–14567.
  • Fernández-Montero JV, Soriano V. Management of hepatitis C in HIV and/or HBV co-infected patients. Best Pract Res Clin Gastroenterol. 2012;26:517–530.
  • Zhou J, Dore G, Zhang F, et al. Hepatitis B and C virus coinfection in the TREAT Asia Observational database. J Gastroenterol Hepatol. 2007;22:1510–1518.
  • Pontisso P, Ruvoletto M, Fattovich G, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology. 1993;105:1529–1533.
  • Chu C, Lee S. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23:512–520.
  • Soriano V, Barreiro P, Martin-Carbonero L, et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J Infect Dis. 2007;195:1181–1183.
  • Liu C, Chen P, Lai M, et al. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003;37:568–576.
  • Liu C, Chuang W, Lee C, et al. Peginterferon alfa-2b plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136:496–504.
  • Collins J, Raphael K, Terry C, et al. Hepatitis B reactivation during successful treatment of hepatitis C with sofosbuvir and simeprevir. Clin Infect Dis. 2015;61:1304–1306.

This study records for the first time two cases of HBV reactivation during successful DAA therapy for hepatitis C.

  • Wahle R, Perez R, Pereira P, et al. Hepatitis B virus reactivation after treatment for hepatitis C in hemodialysis patients with HBV/HCV coinfection. Braz J Infect Dis. 2015;19:533–537.
  • Soriano V, Labarga P, De Mendoza C, et al. Emerging challenges in managing hepatitis B in HIV patients. Curr HIV/AIDS Rep. 2015;12:344–352.
  • Soriano V, Gallego L. Viral hepatitis: treating hepatitis C in injection drug users. Nat Rev Gastroenterol Hepatol. 2013;10:568–569.
  • Robaeys G, Grebely J, Mauss S, et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Clin Infect Dis. 2013;57(suppl 2):129–137.
  • Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis. 2009;49:561–573.
  • Paraskevis D, Nikolopoulos G, Fotiou A, et al. Economic recession and emergence of an HIV-1 outbreak among drug injectors in Athens metropolitan area: a longitudinal study. PLoS One. 2013;8(e78941):1.
  • Strathdee S, Beyrer C. Threading the needle – how to stop the HIV outbreak in rural Indiana. N Engl J Med. 2015;373:397–399.
  • Soriano V, Sherman K, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-HCV coinfected patients. Aids. 2011;25:2197–2208.
  • Altice F, Kamarulzaman A, Soriano V, et al. Treatment of medical, psychiatric, and substance use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376:367–387.
  • Naggie S, Sulkowski M. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology. 2012;142:1324–1334.
  • Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut. 2012;61(suppl 1):47–58.
  • Pineda JA, Nuñez-Torres R, Tellez F, et al. HCV reinfection after sustained virological response in HIV-infected patient with chronic hepatitis C. J Infect. 2015 Jul 23. pii: S0163-4453(15)00231-5. DOI:10.1016/j.jinf.2015.07.006. [Epub ahead of print].
  • Svarovskaia E, Martin R, Chodavarapu K, et al. HCV reinfection cases in phase 3 studies of sofosbuvir. EASL, Vienna, Austria [abstract O063]. J Hepatol. 2015;62(suppl):222–223.
  • Soriano V, Labarga P, De Mendoza C, et al. Acute hepatitis C virus re-infection in a heterosexual HIV-positive partner. Liver Int. 2015 May 2. DOI:10.1111/liv.12858. [Epub ahead of print].
  • Martin T, Martin N, Hickman M, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. Aids. 2013;27:2551–2557.
  • Melin P, Chousterman M, Fontanges T, et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol. 2010;22:1050–1057.
  • Gallego L, Barreiro P, López-Ibor JJ. Diagnosis and clinical features of major neuropsychiatric disorders in HIV infection. AIDS Rev. 2011;13:171–179.
  • Soriano V, Vispo E, Poveda E, et al. Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother. 2012;13:313–323.
  • Barreiro P, Labarga P, Fernandez-Montero JV, et al. Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. J Clin Virol. 2015;71:63–66.
  • Krishnan P, Tripathi R, Schnell G, et al. Resistance analysis of baseline and treatment-emergent variants in the AVIATOR study with paritaprevir/r, ombitasvir and dasabuvir in HCV genotype 1. Antimicrob Agents Chemother. 2015;59:5445–5454.
  • Hedskog C, Dvory-Sobol H, Gontcharova V, et al. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J Viral Hepat. 2015;22:871–881.
  • Yoshimi S, Imamura M, Murakami E, et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol. 2015;87:1913–1920.
  • Krishnan P, Tripathi R, Schnell G, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r, ombitasvir and dasabuvir-based regimens. EASL, Vienna, Austria [abstract O057]. J Hepatol. 2015;62(suppl):220.
  • Dvory-Sobol H, Wyles D, Ouyang W, et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. EASL, Vienna, Austria [abstract O059]. J Hepatol. 2015;62(suppl):221.
  • Buti M, Riveiro-Barciela M, Esteban R. Management of direct antiviral agent failures. J Hepatol. 2015 Aug 20. pii: S0168-8278(15)00552-8. DOI:10.1016/j.jhep.2015.08.010. [Epub ahead of print].
  • Osinusi A, Kohli A, Marti M, et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med. 2014;161:634–638.
  • Lawitz E, Flamm S, Yang J, et al. Re-treatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. EASL, Vienna, Austria [abstract O005]. J Hepatol. 2015;62(suppl):192.
  • Ogawa E, Furusyo N, Dohmen K, et al. Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. J Viral Hepat. 2015;22:992–1001.
  • Sherman A, Sherman K. Extrahepatic manifestations of hepatitis C infection: navigating CHASM. Curr HIV/AIDS Rep. 2015 Sep;12(3):353–361.
  • Soriano V, Labarga P, Fernandez-Montero JV, et al. Hepatitis C cure with antiviral therapy - benefits beyond the liver. Antivir Ther. 2015 Jun 25. DOI:10.3851/IMP2975. [Epub ahead of print].
  • Negro F, Forton D, Craxi A, et al. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015 Aug 28. pii: S0016-5085(15)01203-2. DOI:10.1053/j.gastro.2015.08.035. [Epub ahead of print].
  • Iorio R, Giannattasio A, Sepe A, et al. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis. 2005;41:1431–1437.
  • Serranti D, Indolfi G, Resti M. New treatments for chronic hepatitis C: an overview for paediatricians. World J Gastroenterol. 2014;20:15965–15974.
  • Beste L, Bondurant H, Ioannou G. Prevalence and management of chronic hepatitis C virus infection in women. Med Clin N Am. 2015;99:575–586.
  • Roberts S, Miller R, Jones J, et al. The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009. Birth Defects Res A Clin Mol Teratol. 2010;88:551–559.
  • Vespasiani-Gentilucci U, Galati G, Gallo P, et al. Hepatitis C treatment in the elderly: new possibilities and controversies towards interferon-free regimens. World J Gastroenterol. 2015;21:7412–7426.
  • Renet S, Chaumais MC, Antonini T, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015 Aug 4. pii: S0016-5085(15)01083-5. DOI:10.1053/j.gastro.2015.07.051. [Epub ahead of print].
  • Soriano V, Barreiro P, De Mendoza C. Hypoglycemia in a diabetic patient during hepatitis C therapy. Hepatology. 2015 Aug 27. DOI:10.1002/hep.28137. [Epub ahead of print].
  • Bickerstaff C. The cost-effectiveness of novel direct acting antiviral agent therapies for the treatment of chronic hepatitis C. Expert Rev Pharmacoecon Outcomes Res. 2015;15:787–800.
  • Everhart J, Lok A, Kim H, et al. Weight-related effects on disease progression in the HALT-C trial. Gastroenterology. 2009;137:549–557.
  • Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–1898.
  • Franco S, Tural C, Nevot M, et al. Detection of a sexually transmitted HCV protease inhibitor-resistance variant in a HIV-infected homosexual man. Gastroenterology. 2014;147:599–601.
  • Arends J, Lieveld F, Boeijen L, et al. Natural history and treatment of HCV/HIV coinfection: is it time to change paradigms? J Hepatol. 2015;63:1254–1262.
  • Najafzadeh M, Andersson K, Shrank W, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162:407–419.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.